DUBLIN--(BUSINESS WIRE)--The "Breast Cancer Liquid Biopsy Market by Circulating Biomarkers, Region, End User, Investments, Market Dynamics, Platform Comparison, Competitive Landscape - Global Forecasts to 2022" report has been added to ResearchAndMarkets.com's offering.
The global breast cancer liquid biopsy market is estimated to grow at a CAGR of 23.1% from 2017 to 2022, from USD 145.4 million in 2017 to reach USD 411.1 million by 2022.
Increasing prevalence of breast cancer, increasing preference for noninvasive procedures, and availability of funding for liquid biopsy R&D are some of the key factors driving the growth of the market. Unclear regulatory and reimbursement scenario is one of the major challenges faced by the market.
Based on circulating biomarkers, the market is categorized into circulating tumor cells (CTCs), cell-free DNA (cfDNA), extracellular vesicles (EVs), and other circulating biomarkers. The cfDNA segment is the fastest-growing segment in the circulating biomarkers market during the forecast period. This is due to the growing interest in cfDNA research from biofluids such as the blood of cancer patients as a means of disease diagnosis and therapeutic monitoring.
Based on end user, the market is categorized into reference laboratories, hospitals and physician laboratories, and other end users. The reference laboratories segment is the largest end-user segment of the global breast cancer liquid biopsy market. Reference laboratories are well-equipped large laboratories with facilities for genomic testing of samples, thus receiving major share of samples from hospitals and private practitioners.
Key Topics Covered:
1 Liquid Biopsy: Market at A Glance
2 Liquid Biopsy: Circulating Biomarkers
3 Liquid Biopsy: Market Overview
4 Major Investments & Initiatives
5 Breast Cancer Liquid Biopsy Market
6 Liquid Biopsy Market: Competitive Landscape
7 Appendix
Companies Mentioned
- QIAGEN N.V.
- Roche Diagnostics
- Illumina, Inc.
- Bio-Rad Laboratories
- Myriad Genetics
- Menarini Silicon Biosystems
- Cynvenio Biosystems, Inc.
- Genomic Health, Inc.
- Thermo Fisher Scientific Inc.
- Fluxion Biosciences, Inc.
- Biodesix, Inc.
- Guardant Health, Inc.
- Isogen Life Science B.V.
For more information about this report visit https://www.researchandmarkets.com/research/w66bz9/breast_cancer?w=4
